ストックスクリーナーアプリを入手
12.85
2.58%
-0.35
前日終値:
$13.20
開ける：
$13.2
24時間の取引高:
3,181
Relative Volume:
0.03
時価総額：
$441.80M
収益：
$7,000
当期純損益:
$-41.54M
株価収益率:
-13.83
EPS:
-0.929
ネットキャッシュフロー:
$-20.57M
1週間 パフォーマンス:
-3.89%
1か月 パフォーマンス:
+21.90%
6か月 パフォーマンス:
+5.93%
1年 パフォーマンス:
-4.67%
1日の値動き範囲:
$12.82
$13.37
1週間の範囲:
$12.32
$13.84
52週間の値動き範囲:
$9.85
$16.76
Benitec Biopharma Inc Stock (BNTC) Company Profile
Compare BNTC vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
12.86 | 459.66M | 7,000 | -41.54M | -20.57M | -0.929 |
VRTX
Vertex Pharmaceuticals Inc
|
518.01 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
662.52 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
927.05 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.43 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.49 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-07 | 開始されました | TD Cowen | Buy |
| 2024-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2024-12-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-10-16 | 開始されました | Oppenheimer | Outperform |
| 2024-09-12 | 開始されました | Guggenheim | Buy |
| 2024-07-22 | 開始されました | Leerink Partners | Outperform |
| 2024-06-13 | 開始されました | Piper Sandler | Overweight |
| 2020-10-05 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-04-20 | 開始されました | Ladenburg Thalmann | Buy |
| 2016-02-26 | ダウングレード | Maxim Group | Buy → Hold |
| 2015-12-31 | 繰り返されました | Maxim Group | Buy |
| 2015-09-16 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Benitec Biopharma Inc (BNTC) 最新ニュース
Form 4 Benitec Biopharma Ltd ADR For: 30 June By Investing.com - Investing.com South Africa
Responsive Playbooks and the BNTC Inflection - Stock Traders Daily
Benitec Biopharma (NASDAQ: BNTC) director gifts 51,813 shares to donor-advised fund - Stock Titan
BNTC Stock Price, Quote & Chart - ChartMill
Benitec Biopharma Inc.(NasdaqCM: BNTC) added to Russell 2000 Value Benchmark - marketscreener.com
Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Microcap Value Benchmark Index - marketscreener.com
Benitec Biopharma Inc.(NasdaqCM: BNTC) added to Russell 2500 Value Benchmark - marketscreener.com
Benitec Biopharma Inc Actuals & Estimates (NASDAQ:BNTC) - TradingView
BNTC Forecast — Price Target — Prediction for 2027 - TradingView
Benitec Biopharma Inc (BNTC) Institutional Confidence - TradingKey
Benitec Biopharma Inc (BNTC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Benitec Biopharma Inc (BNTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Understanding the Setup: (BNTC) and Scalable Risk - Stock Traders Daily
Benitec Biopharma Inc (BNTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Benitec Biopharma Inc (BNTC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Benitec Biopharma Inc (BNTC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Benitec Biopharma Inc (BNTC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Benitec Biopharma Inc (BNTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Benitec Biopharma Inc (BNTC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Benitec Biopharma (BNTC) Faces Downgrade Amid Uncertainty - GuruFocus
Guggenheim Downgrades Benitec Biopharma(BNTC.US) to Hold Rating - Moomoo
The Technical Signals Behind (BNTC) That Institutions Follow - Stock Traders Daily
BNTC Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Clinical ProgressInterim Report - newsline.com
Benitec Biopharma (BNTC) Slides 2.22% as Shares Approach Critical SupportDollar Neutral Pair - newsline.com
Benitec Biopharma (BNTC) Stays Flat: Technical Trading Range Defines Near-Term OutlookGamma Flip Level - The Legal Advocate
Benitec Biopharma Announces Board Changes and New Director - The Globe and Mail
Benitec BiopharmaCFO Megan Boston Resigns From Board Effective May 22, 2026 - TradingView
Benitec Biopharma Inc. Announces Board Changes, Effective May 22, 2026 - marketscreener.com
Benitec Biopharma (NASDAQ: BNTC) adds director as CFO exits board role - Stock Titan
Benitec Biopharma (BNTC) director option grant benefits Suvretta-managed funds - Stock Titan
Benitec Biopharma (BNTC) director David Friedman files initial Form 3 - Stock Titan
Precision Trading with Benitec Biopharma Inc. (BNTC) Risk Zones - Stock Traders Daily
BNTCBenitec Biopharma Inc Stock Price and Quote - Finviz
Benitec Biopharma (BNTC) Edges Higher Amid Steady TradingGolden Cross - The Legal Advocate
H.C. Wainwright Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Maintains Target Price $32 - Moomoo
Benitec Biopharma’s SWOT analysis: gene therapy stock shows clinical promise By Investing.com - Investing.com South Africa
Benitec Biopharma’s SWOT analysis: gene therapy stock shows clinical promise - Investing.com Nigeria
Citizens reiterates Benitec BioPharma stock rating on dose data By Investing.com - Investing.com Canada
BNTC News | BENITEC BIOPHARMA INC (NASDAQ:BNTC) - ChartMill
Technical Reactions to BNTC Trends in Macro Strategies - Stock Traders Daily
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update - Sahm
Benitec Biopharma Inc. Q1 2026 10-Q Report: Financial Statements, Risk Factors, and Company Overview - minichart.com.sg
Benitec Biopharma Reports Q3 2026 Results: Strong BB-301 Clinical Progress for OPMD, $184.8M in Cash, Upcoming FDA Milestones - Minichart
Benitec Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Is Benitec Biopharma (BNTC) Fairly Valued After Q3 FY2026 Earnin - GuruFocus
Benitec Biopharma 3Q Loss/Shr 24c >BNTC - Moomoo
Benitec Biopharma Inc. Q3 2026: Revenue $0 Net loss $(11.9M), EPS $(0.24) — 10-Q Summary - TradingView
Benitec Biopharma reports Q3 FY2026 net loss $11.9M, cash $184.8M; advances BB-301 clinical program - TradingView
Benitec Biopharma (NASDAQ: BNTC) raises $100M to fund OPMD gene therapy BB-301 - Stock Titan
Benitec Biopharma Q3 net loss narrows as expenses fall - TradingView
BB-301 data, strong cash position shape Benitec (NASDAQ: BNTC) Q3 2026 - Stock Titan
Benitec Biopharma Inc (BNTC) 財務データ
収益
当期純利益
現金流量
EPS
Benitec Biopharma Inc (BNTC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '25 |
Buy |
12.85 |
50,000 |
642,500 |
9,620,075 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 26 '25 |
Buy |
13.10 |
16,836 |
220,552 |
9,634,395 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 22 '25 |
Buy |
12.08 |
19,542 |
236,067 |
9,577,475 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 19 '25 |
Buy |
11.48 |
16,384 |
188,088 |
9,560,825 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 18 '25 |
Buy |
11.24 |
10,215 |
114,817 |
9,546,875 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 07 '25 |
Buy |
13.50 |
1,481,481 |
19,999,994 |
9,538,175 |
1.95%
0.07%
大文字化:
|
ボリューム (24 時間):